Skip to main content

Table 2 Immunohistochemistry patient data

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Protein Expression No of patients (%) p-value
ITP IP
ERCC 1
 High 11 (50) 9 (42.9) 0.906
 Moderate 5 (22.7) 7 (33.3)  
 Low 2 (9.1) 2 (9.5)  
 None 4 (18.2) 3 (14.3)  
COX 2
 High 7 (31.8) 5 (23.8) 0.342
 Moderate 5 (22.7) 7 (33.3)  
 Low 4 (18.2) 7 (33.3)  
 None 6 (27.3) 2 (9.5)  
III beta tubulin
 High 11 (50) 9 (42.9) 0.425
 Moderate 8 (36.4) 5 (23.8)  
 Low 3 (13.6) 6 (28.6)  
 None 0 (0) 1 (4.8)  
CD4
 High 0 (0) 0 (0) 0.768
 Moderate 3 (13.6) 4 (19)  
 Low 6 (27.3) 7 (33.3)  
 None 13 (59.1) 10 (47.6)  
CD8
 High 1(4.5) 0 (0) 0.226
 Moderate 3 (13.6) 3 (14.3)  
 Low 3 (13.6) 8 (38.1)  
 None 15 (68.2) 10 (47.6)  
  1. ITP Ifosfamide Paclitaxel Cisplatin, IP Ifosfamide Cisplatin